Please contact us for more information or to learn if you are eligible to participate.
This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment.
Principal Investigator | Dr. Jose Cruz |
Co-PI | Edgar Lopez Pacheco |
Sponsor | National Cancer Institute (NCI) |
Type of Trial | Interventional |